In Vitro Synergistic Activity of Antimicrobial Combinations Against Carbapenem- and Colistin-Resistant and

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Jan 21

PMID 36671295

Authors

Paraskevi Mantzana

Efthymia Protonotariou

Angeliki Kassomenaki

Georgios Meletis

Areti Tychala

Eirini Keskilidou

Maria Arhonti

Charikleia Katsanou

Aikaterini Daviti

Olga Vasilaki

Georgia Kagkalou

Lemonia Skoura

Affiliations

Soon will be listed here.

Abstract

Polymyxins are commonly used as the last resort for the treatment of MDR and nosocomial infections; however, apart from the already known toxicity issues, resistance to these agents is emerging. In the present study, we assessed the in vitro synergistic activity of antimicrobial combinations against carbapenem-resistant and colistin-resistant and in an effort to provide more options for their treatment. Two hundred and one hundred and six single clinical isolates with resistance to carbapenems and colistin, recovered between 1 January 2021 and 31 July 2022,were included. were tested by the MIC test strip fixed-ratio method for combinations of colistin with either meropenem or rifampicin or daptomycin. were tested for the combinations of colistin with meropenem and ceftazidime/avibactam with aztreonam. Synergy was observed at: 98.99% for colistin and meropenem against ; 91.52% for colistin and rifampicin; and 100% for colistin and daptomycin. Synergy was also observed at: 73.56% for colistin and meropenem against and; and 93% for ceftazidime/avibactam with aztreonam. The tested antimicrobial combinations presented high synergy rates, rendering them valuable options against and infections.

Citing Articles

A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.

Assefa G, Roberts J, Aslan A, Mohammed S, Sime F J Antimicrob Chemother. 2024; 80(2):334-346.

PMID: 39691958 PMC: 11787894. DOI: 10.1093/jac/dkae451.

Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis.

Hsu W, Chuang M, Tsai W, Lai C, Lai H, Tang H Infection. 2024; 52(5):2029-2042.

PMID: 38739208 DOI: 10.1007/s15010-024-02277-y.

Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant .

Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X Microbiol Spectr. 2024; 12(6):e0010724.

PMID: 38712934 PMC: 11237391. DOI: 10.1128/spectrum.00107-24.

Co-Administration of High-Dose Nebulized Colistin for Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes.

Andrianopoulos I, Kazakos N, Lagos N, Maniatopoulou T, Papathanasiou A, Papathanakos G Antibiotics (Basel). 2024; 13(2).

PMID: 38391555 PMC: 10886014. DOI: 10.3390/antibiotics13020169.

Synergistic Activity of Combinations of Tetrahydroisoquinolines and Treatment Antibiotics against Multidrug-Resistant .

Ndip R, Hanna J, Mbah J, Ghogomu S, Ngemenya M Adv Pharmacol Pharm Sci. 2023; 2023:6142810.

PMID: 38130400 PMC: 10733592. DOI: 10.1155/2023/6142810.

References

Seifert H, Blondeau J, Lucassen K, Utt E . Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018). J Glob Antimicrob Resist. 2022; 31:82-89. DOI: 10.1016/j.jgar.2022.08.002. View

Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E . Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam. Antimicrob Agents Chemother. 2019; 63(12). PMC: 6879249. DOI: 10.1128/AAC.01426-19. View

Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V . Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clin Infect Dis. 2018; 69(5):769-776. DOI: 10.1093/cid/ciy988. View

Ahmed M, Zhong L, Shen C, Yang Y, Doi Y, Tian G . Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect. 2020; 9(1):868-885. PMC: 7241451. DOI: 10.1080/22221751.2020.1754133. View

Park G, Choi J, Jang S, Jeong S, Kim C, Choi I . In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii. Ann Lab Med. 2015; 36(2):124-30. PMC: 4713845. DOI: 10.3343/alm.2016.36.2.124. View

Lemos E, de la Hoz F, Alvis N, Einarson T, Quevedo E, Castaneda C . Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin Microbiol Infect. 2013; 20(2):174-80. DOI: 10.1111/1469-0691.12251. View

Karakonstantis S, Ioannou P, Samonis G, Kofteridis D . Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant . Antibiotics (Basel). 2021; 10(11). PMC: 8615225. DOI: 10.3390/antibiotics10111344. View

Cassini A, Hogberg L, Plachouras D, Quattrocchi A, Hoxha A, Simonsen G . Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2018; 19(1):56-66. PMC: 6300481. DOI: 10.1016/S1473-3099(18)30605-4. View

Karakonstantis S, Kritsotakis E, Gikas A . Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection. 2020; 48(6):835-851. PMC: 7461763. DOI: 10.1007/s15010-020-01520-6. View

10.

Li J, Yang X, Chen L, Duan X, Jiang Z . In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii: A Systematic Review and Meta-Analysis. Microb Drug Resist. 2017; 23(8):982-993. DOI: 10.1089/mdr.2016.0279. View

11.

Meletis G, Protonotariou E, Gkeka I, Kassomenaki A, Mantzana P, Tychala A . In vitro activity of eravacycline and cefoperazone/ sulbactam against extensively-drug resistant and pan-drug resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece. New Microbiol. 2022; 45(3):210-212. View

12.

Xiong L, Wang X, Wang Y, Yu W, Zhou Y, Chi X . Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam. WIREs Mech Dis. 2022; 14(6):e1571. PMC: 9788277. DOI: 10.1002/wsbm.1571. View

13.

Zhen S, Wang H, Feng S . Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections. Infection. 2022; 50(6):1409-1423. DOI: 10.1007/s15010-022-01876-x. View

14.

Hong D, Kim J, Lee H, Yoon E, Jeong S, Yong D . In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis. 2016; 86(2):184-9. DOI: 10.1016/j.diagmicrobio.2016.07.017. View

15.

Gutierrez-Gutierrez B, Salamanca E, Cueto M, Hsueh P, Viale P, Pano-Pardo J . Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017; 17(7):726-734. DOI: 10.1016/S1473-3099(17)30228-1. View

16.

March G, Bratos M . A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii. J Microbiol Methods. 2015; 119:31-6. DOI: 10.1016/j.mimet.2015.09.014. View

17.

Papst L, Beovic B, Pulcini C, Durante-Mangoni E, Rodriguez-Bano J, Kaye K . Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018; 24(10):1070-1076. DOI: 10.1016/j.cmi.2018.01.015. View

18.

Meletis G . Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016; 3(1):15-21. PMC: 4735501. DOI: 10.1177/2049936115621709. View

19.

Cheng A, Chuang Y, Sun H, Sheng W, Yang C, Liao C . Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study. Crit Care Med. 2015; 43(6):1194-204. DOI: 10.1097/CCM.0000000000000933. View

20.

Paul M, Daikos G, Durante-Mangoni E, Yahav D, Carmeli Y, Dishon Benattar Y . Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018; 18(4):391-400. DOI: 10.1016/S1473-3099(18)30099-9. View